Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome

Abstract

Exenatide is a novel and safe treatment option for SBS. It produced substantial improvement in the bowel habits, nutritional status and quality of life of SBS patients. Successful treatment with exenatide may significantly reduce the need for parenteral nutrition and small bowel transplant.